Paraneoplastic Pruritus: Evaluation and Management
For paraneoplastic pruritus, prioritize treating the underlying malignancy first, as this often resolves the itch; for symptomatic relief while awaiting cancer treatment or in refractory cases, use paroxetine, mirtazapine, granisetron, or aprepitant for solid tumors, and cimetidine, gabapentin, carbamazepine, or mirtazapine for lymphoma-associated itch. 1
Initial Evaluation
When evaluating generalized pruritus without primary skin lesions, conduct a systematic workup to identify underlying malignancy:
Laboratory Investigation
- Complete blood count with differential, blood film, lactate dehydrogenase, and ESR to screen for hematological malignancies 1
- Liver function tests (including bile acids and antimitochondrial antibodies if cholestasis suspected) 1
- Urea and electrolytes 1
- JAK2 V617F mutation if polycythemia vera suspected (raised hemoglobin/hematocrit with microcytosis, elevated white cells/platelets, low ESR) 1
Clinical Red Flags to Assess
Look specifically for constitutional symptoms and organ-specific findings 1:
- General: Weight loss, lymphadenopathy, fever, loss of appetite, lethargy
- Breast: Lumps, shape changes, bloodstained nipple discharge
- Colorectal: Persistent bowel habit changes, blood in stool, abdominal pain/bloating
- Lung: Persistent cough, breathlessness, chest/shoulder pain, hoarseness, finger clubbing
- Hepatobiliary: Jaundice, pale stools, dark urine, dysphagia, melaena
Skin Biopsy Consideration
Consider skin biopsy from normal-appearing trunk skin in persistent unexplained pruritus, as cutaneous lymphoma can rarely present with pruritus before visible skin changes 1
Management Algorithm
Step 1: Treat the Underlying Malignancy
Treatment of the cancer itself is the definitive approach and often resolves pruritus completely 1. This should be the primary focus whenever feasible.
Step 2: Symptomatic Management by Cancer Type
For Lymphoma-Associated Pruritus:
First-line options (all Strength D recommendations) 1:
- Cimetidine
- Gabapentin
- Carbamazepine
- Mirtazapine
- Phototherapy (NB-UVB for non-Hodgkin, BB-UVB for Hodgkin lymphoma)
For incurable lymphoma: Oral corticosteroids provide symptomatic relief 1
For Polycythemia Vera-Associated Pruritus:
Multiple options available (Strength D) 1:
- Cytoreductive therapy
- Aspirin 300 mg daily (shown effective in multiple patients)
- Interferon-alpha (dual benefit as cytoreductive agent, though poorly tolerated)
- SSRIs
- PUVA or UVB phototherapy
- Cimetidine or atenolol
For Solid Tumor-Associated Pruritus:
Recommended agents (Strength D) 1:
- Paroxetine (SSRI)
- Mirtazapine (noradrenergic and specific serotonergic antidepressant)
- Granisetron (5-HT3 antagonist)
- Aprepitant (NK1 receptor antagonist)
Important caveat: Antihistamines are generally ineffective for paraneoplastic pruritus from solid tumors 1
Key Clinical Pitfalls
Drug-Induced vs. Paraneoplastic Pruritus
Cancer treatments themselves frequently cause pruritus, particularly:
- Biological therapies (significant side effect per meta-analysis of 33 RCTs) 1
- Epidermal growth factor inhibitors
- Radiotherapy
Action: Review all cancer medications and consider modification or discontinuation if risk-benefit analysis supports this 1
Multifactorial Etiology
Pruritus in malignancy can result from 1:
- True paraneoplastic phenomenon
- Paraneoplastic dermatoses
- Paraneoplastic neuropathy
- Direct skin involvement
- Treatment side effects
Action: Address all contributing factors simultaneously rather than assuming a single cause
Evidence Limitations
The evidence base for paraneoplastic pruritus treatment consists primarily of case reports and small case series (Level 3-4 evidence) 1. Despite low-quality evidence, the recommendations reflect real-world clinical consensus from the British Association of Dermatologists 2018 guidelines [1-1.
Epidemiological Context
While paraneoplastic pruritus is considered rare overall, it is relatively common in specific malignancies like polycythemia vera and lymphoma 2. A population-based cohort study demonstrated that chronic pruritus without skin changes is a risk factor for undiagnosed hematologic and bile duct malignancies 2, emphasizing the importance of thorough evaluation.